Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Since receiving our funding from AstraZeneca, we have raised $81.9 million in gross proceeds from equity financings from several U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sciences, Pivotal bioVenture Partners, TPG Biotechnology Partners, Sofinnova, and Eventide Funds, to advance our pipeline of breakthrough anti-infective products.
With our unique pathogen-targeted approach, we have developed a robust clinical and pre-clinical pipeline of potential first- and best-in-class medicines. This includes small-molecule programs to treat serious multidrug-resistant Gram-negative infections, including Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae, and a single dose oral therapy for susceptible and drug-resistant Neisseria gonorrhoeae.
Our management team and scientists have in-depth knowledge and a track record of discovery and development of innovative anti-infectives from biotech, academia and big pharma. When you work with us, you invest in the energy and determination of a small biotech, combined with the expertise and portfolio of a global pharmaceutical company.
Antibiotic resistance is an increasingly serious threat to global public health that requires action across all government sectors and society. As antibacterial resistance to antibiotics grows, it becomes increasingly difficult to manage a wide range of infections, which often results in poor outcomes for patients and escalating healthcare costs.
We believe in meaningful change.
We are committed to keeping bacterial resistance at bay. And we will never become complacent with substandard medications. Instead, we will continue to create value with new therapies that are precise, effective and safe.
We strive to restore health to people affected by serious infectious disease caused by drug-resistant Gram-negative bacteria–with exactly the right drug in exactly the right way.
This is how we will make the biggest impact.